Revenue performance remains highly erratic, with a 1,290.8% growth spike in 2026Q1 following a period of sustained contraction, highlighting a lack of repeatable commercial revenue streams.
| Sales/Revenue | 6.59M | 54.23K | 2.57M | 2.84M | 6.72M | 0 | 4.1M | 0 |
| Revenue Growth % | 356.16% | -97.89% | -9.68% | -57.72% | - | -100% | - | - |
| Cost of Goods Sold | 50.41K | 43.39K | 1.61M | 2.28M | 4.14M | 0 | 0 | 421.82K |
| COGS % of Revenue | - | 80% | 62.62% | 80.28% | 61.52% | - | - | - |
| Gross Profit | 6.54M | 10.85K | 959.4K | 560.36K | 2.59M | 0 | 4.1M | -421.82K |
| Gross Margin % | 99.24% | 20% | 37.38% | 19.72% | 38.48% | - | 100% | - |
| Gross Profit Growth % | - | -98.87% | 71.21% | -78.33% | - | -100% | 1071.93% | - |
| Operating Expenses | 12.98M | 11.27M | 30.44M | 26.28M | 17.67M | 13.37M | 9.92M | 6.94M |
| OpEx % of Revenue | - | 20777.65% | 1185.88% | 924.68% | 262.79% | - | 242.07% | - |
| Selling, General & Admin | 7.29M | 7.7M | 21.95M | 13.08M | 7.99M | 4.98M | 2.44M | 1.8M |
| SG&A % of Revenue | - | 14200.62% | 854.97% | 460.43% | 118.84% | - | 59.42% | - |
| Research & Development | 5.22M | 5.44M | 6.39M | 7.68M | 9.34M | 8.17M | 7.26M | 5.14M |
| R&D % of Revenue | - | 10036.3% | 248.91% | 270.12% | 138.92% | - | 176.97% | - |
| Other Operating Expenses | 471.94K | -1.88M | 2.1M | 5.52M | 338.46K | 218.47K | 233.04K | 0 |
| Operating Income | -6.45M | -11.26M | -29.48M | -25.72M | -15.08M | -13.37M | -5.82M | -7.37M |
| Operating Margin % | -97.88% | -20757.65% | -1148.5% | -904.96% | -224.32% | - | -142.07% | - |
| Operating Income Growth % | - | 61.81% | -14.63% | -70.55% | -12.8% | -129.51% | 20.92% | - |
| EBITDA | -5.69M | -10.22M | -28.3M | -24.58M | -14.36M | -12.82M | -5.25M | -6.94M |
| EBITDA Margin % | -86.28% | -18836.7% | -1102.36% | -865.02% | -213.64% | - | -128.1% | - |
| EBITDA Growth % | 74.82% | 63.9% | -15.11% | -71.17% | -11.98% | -144.19% | 24.37% | - |
| D&A (Non-Cash Add-back) | 764.81K | 1.04M | 1.18M | 1.14M | 717.85K | 543.6K | 572.87K | 421.82K |
| EBIT | -1.83M | -6.71M | -28.87M | -24.71M | -14.77M | -12.86M | -5.82M | -7.29M |
| Net Interest Income | -488.55K | -1.25M | -1.16M | -283.04K | -126.66K | 505.37K | 22.32K | 72.35K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 505.37K | 22.32K | 72.35K |
| Interest Expense | 488.55K | 1.25M | 1.16M | 283.04K | 126.66K | 0 | 0 | 0 |
| Other Income/Expense | 4.49M | 3.3M | -544.15K | 722.88K | 178.07K | 505.37K | 22.32K | 72.35K |
| Pretax Income | -1.96M | -7.96M | -30.02M | -24.99M | -14.9M | -12.86M | -5.8M | -7.29M |
| Pretax Margin % | -29.73% | -14677.14% | -1169.7% | -879.52% | -221.67% | - | -141.53% | - |
| Income Tax | -330.19K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 16.84% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.63M | -7.96M | -30.02M | -24.99M | -14.9M | -12.86M | -5.78M | -7.29M |
| Net Margin % | -24.73% | -14677.14% | -1169.7% | -879.52% | -221.67% | - | -140.98% | - |
| Net Income Growth % | 93.41% | 73.49% | -20.12% | -67.74% | -15.85% | -122.54% | 20.75% | - |
| Net Income (Continuing) | -1.63M | -7.96M | -30.02M | -24.99M | -14.9M | -12.86M | -5.8M | -7.29M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.78 | -10.63 | -0.77 | -0.70 | -0.42 | -0.36 | -0.16 | -0.21 |
| EPS Growth % | -1234.49% | -1280.52% | -10% | -66.67% | -16.67% | -125% | 23.81% | - |
| EPS (Basic) | - | -10.63 | -0.77 | -0.70 | -0.42 | -0.36 | -0.16 | -0.21 |
| Diluted Shares Outstanding | 2.1M | 2.1M | 38.79M | 35.93M | 35.82M | 35.77M | 36.7M | 36.7M |
| Basic Shares Outstanding | 2.1M | 2.1M | 38.79M | 35.93M | 35.82M | 35.77M | 36.7M | 36.7M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Imminent liquidity and dilution risk
As indicated by the most recent quarterly filings, HCWB's revenue trajectory remains highly erratic, with a 1,290.8% growth spike in 2026Q1 following a period of sustained contraction, suggesting that current income is driven by non-recurring, incidental milestones rather than a repeatable commercial business model.
The extreme quarter-over-quarter fluctuations highlight the absence of a predictable revenue base, which is typical for early-stage clinical firms lacking commercialized assets. Investors should interpret these figures as noise rather than evidence of market adoption, as the company remains entirely dependent on external capital to fund its research pipeline.
Based on the provided financial data, the company's cost structure is dominated by persistent R&D expenditures, which consistently dwarf the negligible revenue generated, underscoring a business model that is currently optimized for clinical development rather than operational efficiency or near-term profitability.
The company maintains a high fixed-cost base to support its proprietary protein engineering platform, resulting in an operating margin that remains deeply negative. Without a transition to a licensing or partnership-driven revenue model, the current expense discipline appears insufficient to offset the ongoing cash burn required to sustain clinical trials.
As reported in the income statement, the company's operating leverage is currently non-existent, with operating margins reaching as low as -528.9% in 2025Q2, reflecting a fundamental disconnect between the scale of infrastructure investment and the lack of meaningful commercial output or recurring revenue streams.
The inability to scale operating income relative to gross profit suggests that the company is in a high-burn phase where every dollar of revenue is insufficient to cover the overhead of maintaining its clinical infrastructure. This lack of operating leverage warrants close monitoring, as it indicates that the company remains highly sensitive to capital market conditions.
According to recent financial disclosures, the company's reliance on equity-based compensation and the rapid depletion of cash reserves suggest that shareholders face significant dilution risks, as the current burn rate appears unsustainable without immediate access to additional non-dilutive funding or a major strategic partnership.
Short-term observers may focus on the binary nature of the company's clinical readouts, but the underlying financial reality points to a potential liquidity crisis. The persistent use of stock-based compensation to preserve cash, while necessary for talent retention, further complicates the equity narrative for existing investors.
Quick answers to the most common questions about buying HCWB stock.
For fiscal year 2025, HCW Biologics Inc. (HCWB) reported total revenue of $0.1M.
HCW Biologics Inc. (HCWB) reported a net loss of $8.0M for the fiscal year ending 2025.
HCW Biologics Inc. (HCWB) reported an operating income of $-11.3M, resulting in an operating profit margin of -20757.6%. This margin reflects the operational efficiency of the business before interest and taxes.
HCW Biologics Inc. (HCWB) generated $0.0M in gross profit for the year, representing a gross profit margin of 20.0%. This demonstrates the company's core pricing power and production efficiency.